AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02236793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone PDGF-BB
Study NCT02438215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX4204
Description: IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
Study NCT02236793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study NCT03685526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cinenses Lung Volume Reduction Reverser System
Description: Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
Study NCT05651217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable urinary catheter
Description: The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
Study NCT05651217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: super smooth antibacterial urinary catheter
Description: the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
Study NCT04509323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A for Injection
Description: Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
Study NCT04461028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal bupivacaine
Description: 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
Study NCT04461028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine with Dexamethasone Solution
Description: 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
Study NCT02491398 — intervention group
Intervention type: DRUG
Intervention: Bendamustine + Rituximab
Study NCT03027141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face recognition task
Description: Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
Study NCT03027141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face recognition task
Description: Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
Study NCT04930211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-Lidocaine
Description: Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
Study NCT02428972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
Study NCT02428972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
Study NCT04323150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed suction systems
Description: Closed suction systems are using for prevention of the ventilator-associated pneumoniae
Study NCT04323150 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional suction system
Description: The using of open (conventional) suctioning
Study NCT05015738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional education
Description: Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
Study NCT05015738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Education supported by digital tools
Description: Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
Study NCT03245580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Core Liver Biopsy
Description: Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
Study NCT02318771 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT
Study NCT00232180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone administered on top of background standard heart failure therapy
Study NCT03457948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization
Description: Undergo TAE
Study NCT03457948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03457948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
Description: Given IV
Study NCT03457948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo yttrium-90 microsphere RE
Study NCT01876602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feeling states exercise intervention
Description: exercise prescription based on intensity of exercise that feels good.
Study NCT01467336 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic rotator cuff repair for all groups
Study NCT01567033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT Curriculum + Health Information
Description: Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
Study NCT02157428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Study NCT02157428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT01881789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally
Study NCT01881789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
Study NCT01881789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants > 75 years of age, at the discretion of the investigator.
Study NCT03801382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paper-Pencil Tests
Description: The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
Study NCT01881789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
Study NCT00834821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Focused Training (PFT)
Description: PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
Study NCT00834821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS) Program
Description: CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
Study NCT02379052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study NCT02379052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02332473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ypeginterferon alfa-2b
Study NCT02332473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Study NCT02332473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor
Study NCT01686113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEFA
Study NCT01272726 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education
Description: Education on the genetics of ADHD and treatment options for ADHD
Study NCT00000396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient self-care education
Study NCT01686113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Study NCT01497834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (Daclatasvir)
Description: Tablets, Oral, 60mg, Once daily, 24 weeks
Study NCT01497834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (Asunaprevir)
Description: Capsules, Oral, 100mg, Twice daily, 24 weeks
Study NCT00499525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV
Study NCT00499525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: given IV
Study NCT00499525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orallly
Study NCT00499525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: given orally
Study NCT02328742 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hysteroscopy + endometrial biopsy
Description: The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study.
Study NCT02328742 — intervention group
Intervention type: OTHER
Intervention: Telephone call
Description: Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study.
Study NCT03571841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Session
Description: The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
Study NCT02328742 — intervention group
Intervention type: BIOLOGICAL
Intervention: Resection + endometrial biopsy
Description: If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study.
Study NCT02328742 — intervention group
Intervention type: BIOLOGICAL
Intervention: Follow-up hysteroscopy + endometrial biopsy
Description: For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study.
Study NCT02909738 — intervention group
Intervention type: OTHER
Intervention: Volunteer to pedal a bicycle
Study NCT03571841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Booster
Description: One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
Study NCT01861054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: 1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
Study NCT02264899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in Memento-VASCOD
Description: * Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement
Study NCT04669470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bariatric endoscopy, mainly intragastric baloons, plication of stomach too
Description: bariatric endoscopy, mainly intragastric baloons, plication of stomach too
Study NCT02435836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study NCT01011036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clobazam
Description: test substance
Study NCT01011036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clonazepam
Description: positive control
Study NCT01011036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tolterodine
Description: active placebo
Study NCT03784521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line filtration
Description: In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
Study NCT03784521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients are treated with standard intravenous solutions and vascular access management
Study NCT03438396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
Study NCT02899832 — intervention group
Intervention type: DEVICE
Intervention: NIRS
Description: Near Infra Red Spectroscopy
Study NCT04393766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline(crystalloids)
Study NCT04393766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: normal saline(crystalloids)
Study NCT01876602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: feeling states exercise intervention
Description: exercise prescription based on intensity of exercise that feels good.
Study NCT01376089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iodixanol
Description: Iodixanol 320 mg I/mL as a single iv. administration.
Study NCT01376089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
Study NCT01888848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry
Description: 12g freeze-dried blueberry (powder), twice daily with water, for 90 days
Study NCT01888848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry Placebo
Description: 12g blue, blueberry-flavored powder, twice daily with water, for 90 days
Study NCT01507038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14617
Description: 1mg once weekly
Study NCT01507038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14617
Description: 1.6mg once weekly
Study NCT02318771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Given IV
Study NCT00569608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Discharge
Description: Application of an early discharge protocol from the neonatal intensive care unit.
Study NCT02893137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: For further information see www.optune.com
Study NCT02893137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniectomy
Description: A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
Study NCT03525743 — intervention group
Intervention type: DEVICE
Intervention: NICOM (Non invasive cardiac output monitor)
Description: Non invasive hemodynamic device utilizing bioreactance
Study NCT00448136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 every 3 weeks
Study NCT00448136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 400mg/m2/day iv on days 1-5 every 6 weeks
Study NCT00448136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozotocin
Description: 500mg/m2/day iv on days 1-5 every 6 weeks
Study NCT00448136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 1000mg/m2 po bid on days 1-14 every 3 weeks
Study NCT01744093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg twice daily (BID orally) x 24 weeks
Study NCT01744093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: 100 mg twice daily (BID orally) x 24 weeks
Study NCT01403064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: IV
Study NCT01403064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: IV Infusion
Study NCT03245957 — intervention group
Intervention type: OTHER
Intervention: Ischemic stroke
Description: Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
Study NCT03245957 — intervention group
Intervention type: OTHER
Intervention: Haemorrhagic stroke
Description: Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
Study NCT02674061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
Study NCT00732433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
Study NCT01507038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14617
Description: 2mg once biweekly
Study NCT01507038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once weekly
Study NCT02190097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Description: see procedures section for more details
Study NCT02190097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association diet
Description: see procedures section
Study NCT01925469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine
Study NCT02727361 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET (Positron Emission Tomography) imaging
Description: Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
Study NCT01925469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: A saline spray will be used in the placebo group
Study NCT04080336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
Study NCT04080336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
Study NCT04080336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.